Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cu-RAX301
- Development stage
- Phase 2
- Lead developer
- RadAlliance Therapeutics
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cu-RAX301 is a copper-64 ([64Cu]) labeled radiopharmaceutical developed by RadAlliance Therapeutics for the diagnostic imaging of prostate cancer. It consists of a high-affinity small molecule ligand (RAX301) that specifically targets the prostate-specific membrane antigen (PSMA), a protein highly expressed on the surface of prostate cancer cells. By utilizing the positron-emitting isotope Copper-64, Cu-RAX301 enables high-resolution PET/CT imaging to detect primary tumors and metastatic lesions. The agent is currently being evaluated in Phase I/II clinical trials (such as the COPRA424 study) for various patient populations, including those scheduled for radical prostatectomy and those with suspected biochemical recurrence of prostate cancer.
- Other names
- [64Cu]-RAX301
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on Cu-RAX301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cu-RAX301.